We’ve worked with leading experts to develop a range of tools and resources to help Employers address the impact of chronic diseases like multiple sclerosis (MS) in the workplace
Estimates are representational only and made available for informational and educational purposes only. Bristol Myers Squibb does not make any representation or warranties with respect to the accuracy, applicability, fitness, or completeness of any estimate generated.
We’ve partnered with the non-profit Caregiver Action Network (CAN) to develop a survey that Employers can use to better understand the prevalence of caregiving among their employees.
We’ve storyboarded a hypothetical conversation between an employee (newly diagnosed with MS) and their Human Resources contact. See what good can sound like.
Learn how one large Employer reduced health plan costs while implementing a successful program to address the unique needs of employees with chronic diseases like MS.
As you evaluate annual benefit offerings for your organization, consider using this framework to support your assessment of health plans and PBM offerings in the area of MS.
The Effect of Chronic Diseases Like MS on Your Organization
Runtime: 16:52
Helping Your Employees with MS and Chronic Disease
Runtime: 16:14
The Financial Realities of MS for Employers & Employees
Runtime: 15:04
Effect on Workplace Productivity
Runtime: 13:00
Understanding the Basics
Runtime: 9:40
To generate a national multiple sclerosis (MS) prevalence estimate for the United States by applying a validated algorithm to multiple administrative health claims (AHC) datasets.
Several AHC datasets representing the US private and government-sponsored insurance programs which included Optum (OP), Truven Health (TH), Kaiser Permanente Southern California (KPSC), Centers for Medicare & Medicaid Services, Department of Defense and Veteran Affairs.
A validated algorithm was applied to each dataset, to determine the 3-year cumulative prevalence overall and stratified by age, sex, and census region for adults (≥18 years of age). Insurance-specific and stratum-specific estimates were applied to the 2010 US Census data. The findings were pooled to calculate the 2010 prevalence of MS in the United States cumulated over 3 years. The study estimated the 2010 prevalence cumulated over 10 years using 2 models and extrapolated the estimate to 2017.
Estimated 2010 US MS prevalence accumulated over 10 years. Also, extrapolated date to 2017 prevalence.
Results may not be generalizable to the entire US population. This study assessed 100% of publicly funded population but not the uninsured population or children 18 years of age within the US.
The content of the linked site is the sole responsibility of the site provider. Bristol Myers Squibb does not control or endorse this third-party website.
Click "OK" to proceed or "CANCEL" to return to ms-workspace.com.
< CancelOK >